Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.

Vibeke StrandStanley B CohenJeffrey R CurtisLixia ZhangAlan J KivitzRobert W LevinAngela MathisErin Connolly-StrongJohanna B Withers

Published in: Expert review of molecular diagnostics (2021)

Adoption of the MSRC into patient care could fundamentally shift treatment paradigms in RA, resulting in substantial improvements in real-world treatment outcomes.

Keyphrases

rheumatoid arthritis
disease activity
ankylosing spondylitis
interstitial lung disease
gene expression
electronic health record
health information
combination therapy
healthcare
bone marrow
replacement therapy
social media
idiopathic pulmonary fibrosis